Telbivudine: a new option for the treatment of chronic hepatitis B

Ruiz-Sancho, Andrés; Sheldon, Julie; Soriano, Vincent

doi:10.1517/14712598.7.5.751

Cited by 37 publications

(22 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, patients with adefovir resistance were more likely to be infected with genotype D [129]. In a phase 3 multicenter trial of latest approved telbivudine, reduction in serum HBV DNA level for genotypes B and C patients at year 2 was 5.9 vs. 5.8 log copies/ml, respectively, for HBeAg-positive patients and 4.7 vs. 5.0 log copies/ml, respectively, for HBeAg-negative patients; the difference was not statistically significant [103]. In summary, these lines of evidence imply that HBV genotype appears to have no substantial impact on the response to nucleoside or nucleotide analogue treatment.…”

Section: Genotypesmentioning

confidence: 88%

“…Recently, of HBeAg-positive patients treated with telbivudine who achieved undetectable serum HBV DNA (\60 IU/ml) at 6 months of therapy, 49% achieved HBeAg seroconversion, 85% achieved ALT normalization, 86% achieved sustained viral suppression, and 98% without resistance at year 2. Similarly, of HBeAg-negative patients, 83% achieved ALT normalization, 88% achieved sustained viral suppression, and 98% without resistance at year 2 [103]. Taking these data together, on-treatment HBV DNA monitoring strategies to identify early viral suppression to an undetectable level would be predictive of better therapeutic outcomes and a greater likelihood of detecting drug resistance.…”

Section: Hbv Factors and Therapy Of Chronic Hepatitismentioning

confidence: 97%

See 1 more Smart Citation

Role of viral factors in the natural course and therapy of chronic hepatitis B

Kao

2007

Hepatol Int

View full text Add to dashboard Cite

Hepatitis B virus (HBV) infection is a global health problem that causes a wide spectrum of liver disease, including acute or fulminant hepatitis, inactive carrier state, chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC). The pathogenesis of hepatocyte damage associated with HBV is mainly through immune-mediated mechanisms. On the basis of the virus and host interactions, the natural history of HBV carriers who are infected in early life can be divided into four dynamic phases. The frequency, extent, and severity of hepatitis flares or acute exacerbation in the second immune clearance and/or fourth reactivation phase predict liver disease progression in HBV carriers. In the past decade, hepatitis B viral factors including serum HBV DNA level, genotype, and naturally occurring mutants predictive of clinical outcomes have been identified. The higher the serum HBV DNA level after the immune clearance phase, the higher the incidence of adverse outcomes over time. In addition, high viral load, genotype C, basal core promoter mutation, and pre-S deletion correlate with increased risk of cirrhosis and HCC development. As to the treatment of chronic hepatitis B, patients with high HBV DNA level and genotype C or D infection are shown to have a worse response to interferon therapy. In conclusion, serum HBV DNA level, genotype, and naturally occurring mutants are identified to influence liver disease progression and therapy of chronic hepatitis B. More investigations are needed to clarify the molecular mechanisms of the viral factors involved in the pathogenesis of each stage of liver disease and the response to antiviral treatments.

show abstract

Section: Genotypesmentioning

confidence: 88%

Section: Hbv Factors and Therapy Of Chronic Hepatitismentioning

confidence: 97%

Role of viral factors in the natural course and therapy of chronic hepatitis B

Kao

2007

Hepatol Int

View full text Add to dashboard Cite

show abstract

“…This is particularly true in view of the recent approval of other antiviral agents for HBV, such as entecavir and telbivudine [38,39], which have a cross-resistant pattern with lamivudine. Mutations at positions rtM204V/I ± rtL180M reduce the antiviral activity of telbivudine and the other L-nucleosides such as emtircitabine, clevudine, and beta-L-2 0 deoxycytidine [40,41].…”

Section: Discussionmentioning

confidence: 99%

Lamivudine-resistant chronic hepatitis B: An observational study on adefovir in monotherapy or in combination with lamivudine

Gaia¹,

Barbon²,

Smedile³

et al. 2008

Journal of Hepatology

View full text Add to dashboard Cite

“…The position of telbivudine (20) as a new option for the treatment of chronic hepatitis B [212] still has to be validated. Meanwhile, peginterferon a-2b has gained wider acceptance in the treatment of chronic hepatitis B patients with advanced fibrosis or cirrhosis [213].…”

Section: Hepadnaviruses (Hepatitis B Virus (Hbv))mentioning

confidence: 99%

Anti‐DNAVirus Agents

Holý

Clercq

2010

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

Anti‐DNA virus agents that are inhibitory to the replication of DNA viruses have been reviewed by Tim Middleton and Rockway in Burger's Medicinal Chemistry, 6th ed., volume 5. Here we will address the various agents effective against these different viruses. For each of the (classes of) compound(s), we will, where applicable, specifically focus on (i) the antiviral compounds that are clinically available; (ii) the antiviral compounds that are under (pre)clinical development; (iii) the mechanism of action of the compounds; (iv) their structure–activity relationship (SAR); (v) resistance that may have arisen; (vi) recent clinical data obtained with the compounds while under development. Previous reviews on antiviral agents have been dealing with “looking back in 2009 at the dawning of antiviral therapy now 50 years ago: an historical perspective,” highlighting the discovery of acyclovir [9‐(2‐hydroxyethoxymethyl)guanine] as a specific antiherpetic agent, “the design of drugs for HIV and HCV,” “HIV drug development: the next 25 years,” “interferons at age 50: past, current, and future impact on biomedicine,” “the way forward in HCV treatment‐finding the right path,” “antiviral treatment of chronic hepatitis B virus infections: the past, the present, and the future,” “antiviral agents active against influenza A viruses,” “the war against influenza: discovery and development of sialidase inhibitors,” “antivirals and antiviral strategies,” and “clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections.”

show abstract

Telbivudine: a new option for the treatment of chronic hepatitis B

Cited by 37 publications

References 59 publications

Role of viral factors in the natural course and therapy of chronic hepatitis B

Role of viral factors in the natural course and therapy of chronic hepatitis B

Lamivudine-resistant chronic hepatitis B: An observational study on adefovir in monotherapy or in combination with lamivudine

Anti‐DNAVirus Agents

Contact Info

Product

Resources

About